anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

218,521-218,580 of 319,975

filter-aware
21
Clinical trial data visualization (waterfall plot) with patient-level characteristics table below.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
22
Swimmer plot showing patient-level treatment duration, response status, and ongoing treatment status.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
23
Includes a spider plot (target lesion change) and a bar chart (allele clearance).Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
24
Includes patient case study with longitudinal MRI scans.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
25
The slide uses a timeline-style list on the left to show treatment history and a visual 'before-and-after' comparison of medical imaging on the right.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
26
Slide 26 of a pitch deck.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
27
Includes clinical trial data cut-offs and patient enrollment numbers.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
28
The slide details specific patient cohorts (2a-2e) with varying treatment histories and trial objectives.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
29
The slide uses a list of icons to define the TPP.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
30
The table highlights the clinical challenge of resistance mutations and CNS involvement across different treatment lines.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
31
The table uses a green/white color coding to indicate positive vs negative results for specific ALK-related activities.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
32
The slide uses a split-panel layout to contrast in vitro IC50 data with in vivo tumor regression data.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
33
The slide uses a bar chart for brain penetrance and a scatter plot for selectivity index to demonstrate the drug's therapeutic profile.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
34
The slide outlines the study design for NVL-655, detailing patient population, objectives, and cohort stratification.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
35
The slide uses a process flow diagram to illustrate patient enrollment and expansion cohorts.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
36
Clinical trial baseline characteristics table.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
37
Data cut-off: 8 Aug 2023. Includes specific footnotes regarding dose modifications and discontinuations.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
38
The chart demonstrates dose-proportional exposure and confirms that doses >= 50 mg QD exceed efficacy thresholds for various ALK mutations in the CNS.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
39
The chart displays patient-level data categorized by dose (15mg to 200mg) and mutation type, highlighting the efficacy of the drug in clearing specific ALK mutations.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
40
The slide presents clinical trial data for NVL-655, showing efficacy across different resistance mutation profiles and prior treatment histories.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
41
Clinical trial data visualization showing ORR and best percentage change in target lesions.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
42
The chart is a swimmer plot, a standard visualization in oncology clinical trials to show time-to-event data for individual patients.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
43
Includes two patient case studies with MRI scans showing tumor reduction.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
44
Includes clinical data points for EML4-ALK v3, G1202R, G1269A, and I1322M.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
45
The slide uses a hierarchical bulleted list to summarize clinical trial conclusions.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
46
The slide uses a clear, icon-based list to define the therapeutic profile.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations 1 hit
47
The slide uses three distinct chart types to demonstrate the drug's competitive advantage in a preclinical setting.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations 1 hit
48
Nuvalent | Investor Presentation Deck | 52 slidesNuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations 1 hit
49
The slide uses a hexagonal process flow to illustrate the company's strategic methodology.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations 1 hit
50
The slide uses a Gantt-style visualization to represent clinical trial progress.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations 1 hit
51
Slide 51 of a pitch deck.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations 1 hit
52
Nuvalent | Investor Presentation Deck | 52 slidesNuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations 1 hit
01
Slide 1
Omnicell | Investor Presentation Deck | 27 slidesOmnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations 1 hit
02
Omnicell | Investor Presentation Deck | 27 slidesOmnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations 1 hit
03
Omnicell | Investor Presentation Deck | 27 slidesOmnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations 1 hit
04
The diagram uses a circular process flow (Assess, Prescribe, Dispense, Administer) surrounding a central 'One Platform' core.Omnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
05
The slide uses a numbered process-style layout to present four distinct strategic advantages.Omnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
06
The slide uses a stepped maturity model framework to show the evolution from manual to fully autonomous pharmacy operations.Omnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations Beat · SolutionLoop · Analogy1 hit
07
The slide uses a semi-circular layout to map specific service offerings to different care environments.Omnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations Beat · SolutionLoop · Analogy1 hit
08
The chart uses a central circle to display the total TAM, with segments radiating outward.Omnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations Beat · Market Size1 hit
09
Omnicell | Investor Presentation Deck | 27 slidesOmnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations Loop · Quick Win Big Bet1 hit
10
The slide highlights the shift toward recurring revenue models through cloud-based services.Omnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations Beat · Financials1 hit
11
The slide uses a before-after framing to justify a shift in business model strategy.Omnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations Beat · Financials1 hit
12
The slide uses a grouped bar chart to compare financial positions over time.Omnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations Beat · Financials1 hit
13
Includes footnotes defining backlog and long-term backlog criteria.Omnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations Beat · Financials1 hit
14
Includes footnotes regarding specific product/service inclusions.Omnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations Beat · Financials1 hit
15
Omnicell | Investor Presentation Deck | 27 slidesOmnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations Beat · Financials1 hit
16
Includes a disclaimer regarding non-GAAP measures and definitions for bookings and TAM.Omnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations Beat · Financials1 hit
17
The slide uses a 2x2 grid layout to present four strategic pillars.Omnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations 1 hit
18
The slide uses a custom framework to map ESG pillars to foundational elements (Targets, Risk Management, Governance and Reporting).Omnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations 1 hit
19
Omnicell | Investor Presentation Deck | 27 slidesOmnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations 1 hit
20
Omnicell | Investor Presentation Deck | 27 slidesOmnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations 1 hit
21
Omnicell | Investor Presentation Deck | 27 slidesOmnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations 1 hit
22
Includes specific line items for share-based compensation, amortization, and one-time costs like ransomware-related expenses and executive transition costs.Omnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations 1 hit
23
Includes footnotes (a) and (d) explaining tax effects and specific litigation expenses.Omnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations 1 hit
24
Includes footnotes (a) through (d) explaining specific adjustments and tax calculations.Omnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations 1 hit
25
The table provides a bridge between GAAP net income and non-GAAP EBITDA, detailing specific adjustments like share-based compensation, interest, depreciation, and other one-time items.Omnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations 1 hit
26
Includes footnote defining Net Debt/EBITDA calculation.Omnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations 1 hit
27
Omnicell | Investor Presentation Deck | 27 slidesOmnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations 1 hit
01
Slide 1
On Holding | Investor Day Presentation Deck | 137 slidesOn Holding | Investor Day Presentation Deck | 137 slides · On Holding
Conference presentation Investor relations Beat · Attention1 hit